Geode Capital Management’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-41,907
| Closed | -$893K | – | 4656 |
|
|
2024
Q1 | $893K | Buy |
41,907
+2,561
| +7% | +$30.6K | ﹤0.01% | 3407 |
|
|
2023
Q4 | $378K | Buy |
39,346
+8,478
| +27% | +$41.2K | ﹤0.01% | 3718 |
|
|
2023
Q3 | $80.3K | Buy |
30,868
+494
| +2% | +$1.58K | ﹤0.01% | 4314 |
|
|
2023
Q2 | $142K | Buy |
30,374
+5,238
| +21% | +$22.6K | ﹤0.01% | 4201 |
|
|
2023
Q1 | $94.8K | Hold |
25,136
| – | – | ﹤0.01% | 4354 |
|
|
2022
Q4 | $79K | Hold |
25,136
| – | – | ﹤0.01% | 4476 |
|
|
2022
Q3 | $75K | Hold |
25,136
| – | – | ﹤0.01% | 4678 |
|
|
2022
Q2 | $62K | Hold |
25,136
| – | – | ﹤0.01% | 4729 |
|
|
2022
Q1 | $195K | Hold |
25,136
| – | – | ﹤0.01% | 4398 |
|
|
2021
Q4 | $104K | Hold |
25,136
| – | – | ﹤0.01% | 4721 |
|
|
2021
Q3 | $199K | Buy |
25,136
+2,047
| +9% | +$17.2K | ﹤0.01% | 4451 |
|
|
2021
Q2 | $186K | Hold |
23,089
| – | – | ﹤0.01% | 4365 |
|
|
2021
Q1 | $247K | Hold |
23,089
| – | – | ﹤0.01% | 4052 |
|
|
2020
Q4 | $271K | Hold |
23,089
| – | – | ﹤0.01% | 3794 |
|
|
2020
Q3 | $277K | Buy |
+23,089
| New | +$316K | ﹤0.01% | 3616 |
|
Geode Capital Management's FUSN Position: Q2 2024 in Review
Geode Capital Management sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q2 2024, closing a stake of 41,907 shares — an estimated $893K sold.
Geode Capital Management first reported a position in FUSN in Q3 2020 and held it in 15 quarters. The position peaked at $893K in Q1 2024. 0 funds tracked by Wall St. Rank hold FUSN as of Q2 2024.
- Geode Capital Management reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q2 2024 after selling out during the quarter.
- Geode Capital Management sold 41,907 Fusion Pharmaceuticals Inc. Common Shares shares in Q2 2024, an estimated $893K.
- Geode Capital Management first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q3 2020 and held it in 15 quarters.
- Geode Capital Management's Fusion Pharmaceuticals Inc. Common Shares position peaked at $893K in Q1 2024.
- 0 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q2 2024.
Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.